Consequently, we propose that CA12 is an interesting candidate for targeted therapy in luminal A and luminal B patients, while LRRC15, EFNA3, and TSPAN13 represent potential targets for the treatment of any molecular subtype of BC, particularly TNBC patients. This evidence concerns the gene EFNA3 and breast cancer.